Showing results (2031-2040 of 2,093) with videos related to
Sort By:
Pageof 210
JAMA Network Open|June 7, 2022
Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United StatesSally B Coburn, Elizabeth Humes, Raynell Lang, et al.The Journal of Molecular Diagnostics : JMD|May 16, 2017
Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx StudyLaura J Rasmussen-Torvik, Berta Almoguera, Kimberly F Doheny, et al.Cancer|March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptorGlenwood D Goss, Everett E Vokes, Michael S Gordon, et al.The Oncologist|June 10, 2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerAlexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 9, 2020
Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort StudyE Jennifer Edelman, Yu Li, Declan Barry, et al.Nano Letters|March 21, 2015
Pathway to the piezoelectronic transduction logic deviceP M Solomon, B A Bryce, M A Kuroda, et al.European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.Investigational New Drugs|March 3, 2023
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumorsAntonio Jimeno, Joaquina Baranda, Wade T Iams, et al.BMC Medical Education|February 3, 2023
What internal medicine attendings talk about at morning report: a multicenter studyJeffrey W Redinger, Daniel B Heppe, Tyler J Albert, et al.Pageof 210